Get the Stockscreener App
38.13
1.09%
0.41
Soleno Therapeutics Inc stock is traded at $38.13, with a volume of 1.12M.
It is up +1.09% in the last 24 hours and down -9.47% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
See More
Previous Close:
$37.72
Open:
$37.8
24h Volume:
1.12M
Relative Volume:
0.75
Market Cap:
$2.05B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-12.72
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
-7.02%
1M Performance:
-9.47%
6M Performance:
-45.19%
1Y Performance:
-14.20%
1-Day Range:
$37.71
$39.27
1-Week Range:
$32.63
$41.86
52-Week Range:
$32.63
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
38.13 | 2.03B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy - Bitget
SLNO: VYKAT XR sees rapid adoption, strong coverage, and expansion plans in rare disease markets - TradingView
SLNO: VYKAT XR's launch drives strong revenue and coverage, with expansion into Europe and new indications planned - TradingView
HC Wainwright Lowers Soleno Therapeutics (NASDAQ:SLNO) Price Target to $100.00 - MarketBeat
H.C. Wainwright cuts Soleno Therapeutics stock price target to $100 - Investing.com UK
SLNO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard Group Inc. Purchases 319,317 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Rafferty Asset Management LLC Purchases 45,076 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Shares Gap UpStill a Buy? - MarketBeat
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring a 178.79% Potential Upside in Rare Disease Therapeutics - DirectorsTalk Interviews
Q1 EPS Forecast for Soleno Therapeutics Raised by Analyst - MarketBeat
How Profitability from VYKAT XR and a New CFO Will Impact Soleno Therapeutics (SLNO) Investors - simplywall.st
Tangible book value per share of Soleno Therapeutics Inc – SWB:6XC - TradingView
SLNOForm S-8Securities to be offered to employees in employee benefit plans - mx.advfn.com
JPMorgan Chase & Co. Buys 140,779 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114Here's Why - Finviz
Soleno Therapeutics Q4 Profitability Milestone Tests High P/E Narrative - Sahm
Soleno (SLNO) Q4 2025 Earnings Call Transcript - AOL.com
Soleno Profitability Milestone And CFO Shift Raise Valuation Questions - Yahoo Finance
Soleno Therapeutics Stock Pre-Market (+9.2%): Strong Q4 Earnings Beat & Profitability - Trefis
Soleno Therapeutics (NASDAQ:SLNO) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Price Target Cut to $110.00 by Analysts at Wells Fargo & Company - MarketBeat
Westfield Capital Management Co. LP Reduces Stock Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (PRCT), Soleno Therapeutics (SLNO) and Agilent (A) - The Globe and Mail
Soleno Therapeutics names Jennifer Fulk as CFO By Investing.com - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Given New $85.00 Price Target at TD Cowen - MarketBeat
Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Soleno Therapeutics stock hits 52-week low at 37.95 USD - Investing.com Nigeria
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year LowShould You Sell? - MarketBeat
Soleno Therapeutics Names New Chief Financial Officer - marketscreener.com
Soleno Therapeutics stock hits 52-week low at 36.01 USD - Investing.com
Eli Lilly (LLY) Veteran Joins Soleno Therapeutics as CFO - GuruFocus
Soleno Therapeutics names Jennifer Fulk as CFO - Investing.com
Soleno Therapeutics Appoints Jennifer Fulk As Chief Financial Officer - Nasdaq
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer - The Manila Times
Eli Lilly veteran Jennifer Fulk to lead finances at rare disease firm Soleno - Stock Titan
Soleno Therapeutics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Soleno Therapeutics Announces New Chief Financial Officer Appointment - TipRanks
Biopharmaceutical company Soleno Therapeutics recently announced a major personnel appointment - Bitget
New CFO for Soleno Therapeutics (NASDAQ: SLNO) as Fulk replaces Mackaness - Stock Titan
30,474 Shares in Soleno Therapeutics, Inc. $SLNO Bought by State of New Jersey Common Pension Fund D - MarketBeat
A Look At Soleno Therapeutics (SLNO) Valuation After Its Shift To Profitability And Earnings Beat - simplywall.st
Soleno Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations By Investing.com - Investing.com Australia
SLNO: VYKAT XR achieved rapid adoption, strong revenue, and profitability in its first year post-launch - TradingView
Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations - Investing.com
Soleno Therapeutics (NASDAQ:SLNO) Announces Earnings Results - MarketBeat
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q4 Revenue $91.7M, vs. FactSet Est of $88.8M - marketscreener.com
Soleno Therapeutics (SLNO) turns profitable after FDA-approved VYKAT XR launch in PWS - Stock Titan
Soleno Therapeutics earnings beat by $0.19, revenue topped estimates - Investing.com
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):